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health and functioning, and is limited to Medicare claims. For
each year of MCBS sample, individuals with incident stroke were
identiﬁed from primary or secondary diagnoses on inpatient
claims records using ICD-9 codes 433, 434, 436, and 437. Fol-
lowing stroke, three measures of health status including general
health, activities of daily living (ADL), and instrumental activi-
ties of daily living (IADL) were determined and indexed to the
stroke date. Medicare expenditures for all health care services
during the same period as health assessments were determined
from billing records and indexed. Severity measures including co-
morbidities, length of hospital stay, and nursing-home admis-
sions were determined from billing records. Analyses included
descriptive statistics and bivariate analyses using t-tests and chi-
square with signiﬁcance level of 0.05. RESULTS: We identiﬁed
1125 beneﬁciaries with an incident stroke. Lower levels of health
on all three measures of health status were associated with higher
mean (SD) expenditures: $6756 ($1432) for fair to poor health
compared to $2759 ($6500) for good to excellent health; $6519
($11,373) for 3 or more ADL limitations compared to $3899
($13,782) for less limitations; and $5988 ($9019) for 3 or more
IADL limitations compared to $4774 ($13,413) for less limita-
tions. Overall, expenditures showed declining trends post-stroke.
CONCLUSION: Preliminary ﬁndings suggest that health status
and time since stroke affect expenditures. Multivariate analyses
using generalized estimating equations will be conducted to
conﬁrm these ﬁndings.
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OBJECTIVES: Clinical trials indicate that the development of
heart failure (HF) impacts post-myocardial infarction (MI) prog-
nosis. There is little information available on the economic
burden of HF in post-MI patients, outside of a clinical trial
setting. This study examines and compares the impact of devel-
oping HF on cost of care and length of stay (LOS) in patients
hospitalized for MI using alternative models for estimation.
METHODS: Claims data for patients hospitalized with a prin-
cipal diagnosis of MI between 1998 and 2000 were used to
compare cost of care and LOS between those with and without
HF at initial hospitalization. Patients with a diagnosis of HF in
the 6-months preceding the MI were excluded. Total hospital-
ization costs and LOS were analyzed for 15,160 patients using
OLS, log-OLS and generalized linear models (GLM). Bootstrap-
ping was used to obtain variances for cost estimates. Age, gender,
type of MI, death, Medicare/non-Medicare, and comorbidities
were included as covariates in the models. RESULTS: Compar-
ing post-MI patients who develop HF during initial hospitaliza-
tion (N = 2968) to those without HF at initial hospitalization (N
= 12,192) the mean incremental cost and incremental LOS were
$7098 (SD = $434), and 3 days (SD = 0.13) respectively using
the GLM. Based on several diagnostic tests, GLM was found to
be the best estimator as long as the link function used is appro-
priate. Log-OLS estimates were biased both due to het-
eroscedasticity and the inappropriateness of log-transformation.
OLS estimates were both biased and inefﬁcient especially for
costs. CONCLUSIONS: Patients who develop post-MI HF
during initial hospitalization for MI have signiﬁcantly higher
hospitalization costs and increased LOS as compared to patients
without post-MI HF. Treatments aimed at preventing or delay-
ing the onset of post-MI HF could result in signiﬁcant cost
savings.
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OBJECTIVE: The model compares—from a health system’s 
perspective—the cardiovascular events avoided and costs of six
angiotensin receptor blockers (ARBs) in treating mildly-to-
moderately hypertensive patients. METHODS: The model con-
siders three potential differences in effectiveness among ARBs:
1) ofﬁce cuff systolic blood pressure (SBP) reduction; 2) 24-hour
ambulatory systolic blood pressure (ABP), and 3) non-compli-
ance. The model uses point estimates of SBP reductions from
published trials and meta-analyses identiﬁed from Medline and
searches of retrieved literature published after 1996. Risks before
and after a SBP reduction are estimated using the Framingham
cardiovascular risk equation for a hypothetical population of
hypertensives. Improved 24-hour ABP confers additional risk
reduction, while non-compliance mitigates the reduction depend-
ing on each ARB’s duration of effect. Drug costs are based on
wholesale acquisition cost and average dosing from IMS national
estimates for 2003. RESULTS: Over a 5-year timeframe in a rep-
resentative hypertensive population, ARBs reduce cardiovascu-
lar events by 15% to 25% at a yearly cost of $185 to $301 per
treated patient or $34,914 to $90,487 per event avoided. The
NNT to avoid one event varies from 37.6 for telmisartan to 62.2
for valsartan. Over 5-years, relative to telmisartan, the model
predicts 547 (olmesartan) to 1052 (valsartan) more cardiovas-
cular events per 100,000 hypertensive patients. Telmisartan gen-
erates cost savings relative to all ARBs. Assuming no difference
between ARBs in cuff SBP reduction, the effects of ABP and non-
compliance alone favor telmisartan by 398 to 696 events. The
model is sensitive to factors that substantially impact cardiovas-
cular risk like patient age and is more sensitive to ABP differ-
ences than to noncompliance. CONCLUSION: Small differences
in SBP reduction between ARBs may produce meaningful dif-
ferences in the number of cardiovascular events avoided. Telmis-
artan’s smooth ABP proﬁle and reduced consequences from
non-compliance relative to other ARBs enhance its effectiveness.
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OBJECTIVE: A literature search revealed a lack of information
on how to treat patients who have failed to meet goal LDL level
on statin therapy. The purpose of this retrospective, cohort study
was to compare the cost-effectiveness of increasing the statin
dose, changing to a different statin, adding an alternative therapy
to the statin, changing to a different therapy, or not making any
changes. METHODS: Medical charts of patients (n = 64) in a
lipid clinic were utilized to gather patient demographics, CHD
risk factors, treatment history, and laboratory values. Effective-
ness was measured by whether the patient met goal LDL levels.
Intervention costs included the cost of the medications, physi-
cian visits, and laboratory tests. RESULTS: The lowest total
average cost occurred when the statin was changed to an alter-
native therapy ($96.39), followed by changing to a different
statin ($131.40), increasing the statin dose ($134.69), making no
change in therapy ($137.95), and adding an additional therapy
to the statin ($153.03). The probability of a patient meeting LDL
